Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2020 Mar;11(3):810-818.
doi: 10.1111/1759-7714.13327. Epub 2020 Feb 4.

Clinical diagnosis and treatment recommendations for ocular toxicities of targeted therapy and immune checkpoint inhibitor therapy

Xiaowei Liu  1 , Zheng Wang  2 , Chan Zhao  1 , Hanping Wang  3 , Xiaoxiao Guo  4 , Jiaxin Zhou  5 , Lian Duan  6 , Xiaoyan Si  3 , Li Zhang  7 , Yue Li  8 , Mengzhao Wang  3 , Meifen Zhang  1 , Li Zhang  3
Affiliations
Review

Clinical diagnosis and treatment recommendations for ocular toxicities of targeted therapy and immune checkpoint inhibitor therapy

Xiaowei Liu et al. Thorac Cancer. 2020 Mar.

Abstract

The increased use of targeted therapy and immune checkpoint inhibitors in cancers has brought new hope of survival to patients with advanced tumors. However, increasing numbers of immune-related adverse events (irAEs) of these medications have been reported, affecting almost all human organs including the eye. These adverse effects may affect the entire ocular region, including the eyelid, eye lashes, conjunctiva, cornea, uvea, retina and optic nerve, and have thus far been largely ignored by patients and doctors. In this review, we summarize the characteristics of ocular diseases related to irAEs and advise on how to diagnose and manage these diseases. KEY POINTS: This review will enable clinical oncologists to recognize, diagnose, and manage targeted therapy and immune checkpoint inhibitor-related ocular adverse events.

Keywords: Immune checkpoint inhibitor; immune-related adverse events (irAEs); ocular toxicities; targeted therapy.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Normal fundus.
Figure 2
Figure 2
“Sunset glow fundus” in a VKH patient.
Figure 3
Figure 3
Eyelid skin vitiligo and poliosis of the eyelashes in a VKH patient.
Figure 4
Figure 4
Retinal serum detachment of the central retina in a PD1 antibody‐treated patient.
See this image and copyright information in PMC

References

    1. Patnaik A, Kang SP, Rasco D et al Phase I study of Pembrolizumab (MK‐3475; anti‐PD‐1 monoclonal antibody) in patients with advanced solid tumors. Clin Cancer Res 2015; 21 (19): 4286–93. - PubMed
    1. Miserocchi E, Cimminiello C, Mazzola M, Russo V, Modorati GM. New‐onset uveitis during CTLA‐4 blockade therapy with ipilimumab in metastatic melanoma patient. Can J Ophthalmol 2015; 50 (1): e2–4. - PubMed
    1. Basilious A, Lloyd JC. Posterior subcapsular cataracts and hypotony secondary to severe pembrolizumab induced uveitis: Case report. Can J Ophthalmol 2016; 51 (1): e4–6. - PubMed
    1. Abu Samra K, Valdes‐Navarro M, Lee S, Swan R, Foster CS, Anesi SD. A case of bilateral uveitis and papillitis in a patient treated with pembrolizumab. Eur J Ophthalmol 2016; 26 (3): e46–8. - PubMed
    1. Khoja L, Atenafu EG, Ye Q et al Real‐world efficacy, toxicity and clinical management of ipilimumab treatment in metastatic melanoma. Oncol Lett 2016; 11 (2): 1581–5. - PMC - PubMed

Publication types

MeSH terms

Substances